Investors

Expedeon AG adds five new Alexa Fluor labels to its Lightning-Link antibody labeling kit range

Heidelberg, Germany and Cambridge, UK, 14 August 2018 – Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced the introduction of five new Alexa Fluor® labels to its range of Lightning-Link® antibody labelling kits. The addition further expands Expedeon’s range of labels, offering customers increased choice and flexibility for common fluorescence detection based applications.

The use of secondary antibodies within fluorescent imaging applications is commonly associated with issues such as high background fluorescence and non-specific binding. The combination of Alexa Fluor labels with Lightning-Link technology overcomes these problems, by enabling easy, direct conjugation of the label to primary antibodies in less than 20 minutes. The Lightning-Link protocol is free of separation steps, saving researchers time and precious materials.

The introduction of five new dyes to the range follows the successful launch of the Alexa Fluor 488 kit in Q2 2017. The new Alexa dyes include: 647, 700, 555, 568, and 694. More information can be found here: https://www.expedeon.com/lightning-link-alexa-fluor-antibody-labeling-kits/

Dr. Heikki Lanckriet, CEO and CSO of Expedeon, said: “Uniting the leading fluorescent labels with the world’s easiest to use primary antibody labeling technology forms part of our strategy to maximise the impact of our core technologies. The new kits will help to simplify processes and increase efficiency in the lab, making a great difference to many researchers.”

About Expedeon AG: www.expedeon.com
Expedeon is an enabler of exciting advances in medical science and patient care. The Company’s core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon’s technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers’ development and commercialisation objectives. Expedeon’s products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXN; ISIN: DE000A1RFM03).